Article
Astellas Pharma US, Inc. has announced that mirabegron (Myrbetriq), indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, is now available through U.S. pharmacies.
Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC
Pearls & Perspectives: Premature ejaculation, with Brian L. Steixner, MD
Drinking water contaminants could increase risk of kidney stones, study finds
Introducing Pearls & Perspectives, with Amy Pearlman, MD!
ADAM, a long-term, injectable male birth control, shows promise at AUA 2025
ADVANCED-002: High CR rates observed with TARA-002 in high-grade NMIBC